Compare PZZA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | CERT |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | United States | United States |
| Employees | N/A | 1546 |
| Industry | Restaurants | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1993 | 2020 |
| Metric | PZZA | CERT |
|---|---|---|
| Price | $41.51 | $8.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $49.44 | $13.88 |
| AVG Volume (30 Days) | 765.6K | ★ 2.0M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | 0.07 |
| Revenue | ★ $2,086,399,000.00 | $415,551,000.00 |
| Revenue This Year | $2.60 | $10.82 |
| Revenue Next Year | N/A | $6.77 |
| P/E Ratio | ★ $36.38 | $126.84 |
| Revenue Growth | N/A | ★ 11.47 |
| 52 Week Low | $30.16 | $8.03 |
| 52 Week High | $55.74 | $15.69 |
| Indicator | PZZA | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 40.96 |
| Support Level | $40.53 | $8.95 |
| Resistance Level | $42.77 | $9.42 |
| Average True Range (ATR) | 1.23 | 0.39 |
| MACD | 0.28 | 0.07 |
| Stochastic Oscillator | 29.67 | 25.99 |
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.